NCT06911073Completed
A Study to Evaluate a Postbiotic in Supporting Weight Loss and Metabolic Health
A Double-Blind, Randomized Placebo-Controlled Study to Evaluate a Postbiotic Supplement in Supporting Weight Loss and Metabolic Health
Source: ClinicalTrials.gov · Last updated 14 Aug 2026
Brief summary (registry, in English)
This study aims to evaluate the impact of a specific oral postbiotic supplement on metabolic health in overweight adults.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 80 (actual)
- First submitted
- 20 Mar 2025
- Start date
- May 2025
- Primary completion date
- Mar 2026
- Lead sponsor
- ResBiotic Nutrition, Inc.
- Diseases
- Obesity
- NCT number
- NCT06911073
What you commit to
- Study type: Interventional
- Participants enrolled: 80
- From May 2025 to the primary completion date, Mar 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Alcohol abuse (more than 2 standard alcoholic drinks per day or more than 10 drinks per week) or drug abuse or dependence within the past 6 months.
- Previous bariatric surgery.
- Previous medical diagnosis of gout or fibromyalgia.
- Pregnant women, women trying to become pregnant, women less than 120 days postpartum or nursing women. Any woman that is sexually active will have to take report their pregnancy status prior to enrolling and during the trial if they become pregnant.
- Currently participating in another research study with an investigational product or have been in another research study in the past 30 days.
Other illness
- History of unstable or new-onset cardiovascular/cardiorespiratory, liver, or renal conditions.
- History of hyperparathyroidism or an untreated thyroid condition.
- History of malignancy in the previous 5 years except for non-melanoma skin cancer (basal cell cancer or squamous cell cancer of the skin).
- Other known gastrointestinal or metabolic conditions that might impact nutrient absorption or metabolism, e.g., short bowel syndrome, irritable bowel syndrome (IBS), diarrheal illnesses, history of colon resection, gastroparesis, Inborn-Errors-of-Metabolism (such as PKU).
- Chronic inflammatory condition (e.g., rheumatoid arthritis, Crohn's, ulcerative colitis, Lupus, HIV/AIDS, etc.).
Other
- Current smokers or smoking within the past month.
- Known sensitivity to any ingredient in the test formulations as listed in the product label.
Who the study is looking for
- Provide voluntary signed and dated informed consent.
- Be in good health as determined by medical history.
- Age between 18 and 65 yr (inclusive).
- Body Mass Index of 25.0 - 40.0 (inclusive).
- Subject agrees to maintain existing dietary and physical activity patterns throughout the study period.
- Agree to refrain from other probiotic and postbiotic supplement products throughout the duration of the trial.
- Subject is willing and able to comply with the study protocol.
- Willing and able to agree to the requirements and restrictions of this study, be willing to give voluntary consent, be able to understand and read the questionnaires, and carry out all study-related procedures.
Age in the registry: 18 years to 65 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Able Biolabs, LLC Coordinator of this site? Confirm its status | Birmingham | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.